Skip to main content
Premium Trial:

Request an Annual Quote

Independence Blue Cross to Cover MDxHealth Prostate Cancer Test

NEW YORK (GenomeWeb) – MDxHealth announced today that it has received a positive coverage determination from Independence Blue Cross for its ConfirmMDx for Prostate Cancer test.

Independence, a member of the Blue Cross Blue Shield Association (BCBSA), provides insurance coverage for patients in 32 states and Washington, DC. The company's coverage decision marks the first time a BCBSA plan has approved coverage for ConfirmMDx, MDxHealth said.

In March, the test was included in the US 2016 National Comprehensive Cancer Network (NCCN) Guidelines for prostate cancer screening. "Tests that improve specificity in the post-biopsy state — including 4Kscore, PHI, percent free PSA, PCA3, and ConfirmMDx — should be considered in patients thought to be higher risk despite a negative prostate biopsy," according to the NCCN guidelines.

ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns. It has qualified for Medicare, Medicare Advantage, and other private reimbursement plans, MDxHealth said.

"This positive coverage decision by Independence Blue Cross is a significant milestone as we work towards achieving nationwide payer adoption of our ConfirmMDx for Prostate Cancer test," said MDxHealth CEO Jan Groen in a statement. "This decision demonstrates that our investment in clinical studies and our work with managed care organizations in the US continues to yield positive results."

The company has received several positive coverage decisions in recent months. In June, the company signed a coverage agreement with Michigan-based health plan Priority Health. In August, MDxHealth received a positive medical policy decision from Cigna for ConfirmMDx. And earlier this month, ConfirmMDx was included as an in-network benefit under the California Medical Assistance Program.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.